Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy developer and manufacturer Cellares to produce a CAR-T cell therapy. This collaboration will utilize Cellares’ clinical and commercial-stage manufacturing platform following a proof-of-concept technology transfer, which is expected to be completed within months.
Advantages of Cellares’ Manufacturing Platform
Cellares prides itself on its high-throughput process, which is automated, standardized, cost-efficient, and scalable. The platform is capable of supporting both autologous and allogeneic cell therapy processes, as well as most cell therapy modalities. This partnership with BMS is a significant step towards advancing the production capabilities for CAR-T cell therapies.
Implications for CAR-T Cell Therapy Development
The agreement with Cellares aligns with BMS’s commitment to leveraging innovative manufacturing technologies to enhance the development and production of CAR-T cell therapies. By adopting Cellares’ platform, BMS aims to improve the efficiency and scalability of its CAR-T cell therapy production, potentially leading to better patient outcomes and more accessible treatments.-Fineline Info & Tech
